Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With a new series B round and additional cash, Imcyse will take its Imotopes into Phase II

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells.

Announced Tuesday, the cash infusion includes €28 million ($31.4 million) in a series B round led by

Read the full 433 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE